Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04931654 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

A Phase 1 study of Gastric Cancer and Carcinoma, Non-Small Cell Lung, sponsored by AstraZeneca.

Active
Registry status
Phase 1
Development phase
136
Enrollment target
20
Study locations

NCT04931654 is a Phase 1 study of Gastric Cancer and Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 136 participants, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04931654, a Phase 1 study of Gastric Cancer and Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
136 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.

Conditions Studied

Gastric Cancer Carcinoma, Non-Small Cell Lung Gastroesophageal-junction Cancer

Interventions

  • DRUG AZD7789

Study Locations (20)

Other

  • Research Site - Beijing
  • Research Site - Guangzhou
  • Research Site - Bordeaux
  • Research Site - Rennes
  • Research Site - Villejuif
  • Research Site - Tbilisi
  • Research Site - Chūōku
  • Research Site - Kashiwa
  • Research Site - Chisinau
  • Research Site - Amsterdam
  • Research Site - Barcelona
  • Research Site - Madrid
  • Research Site - Ankara
  • Research Site - Ankara
  • Research Site - Ankara

Georgia

  • Research Site - Atlanta

Indiana

  • Research Site - Fort Wayne

New York

  • Research Site - New York

Tennessee

  • Research Site - Nashville

Ontario

  • Research Site - Toronto

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2021-09-28
Est. Completion 2026-08-12
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04931654

The ClinicalTrials.gov registry entry for NCT04931654 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (57% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which AZD7789 is the first listed.

NCT04931654 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Georgia, Indiana.

Frequently Asked Questions

What is clinical trial NCT04931654 about?

NCT04931654 is a clinical study titled "A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer". This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.

What is the current status of trial NCT04931654?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2021-09-28. Estimated completion is 2026-08-12.

What conditions does trial NCT04931654 study?

This clinical trial studies the following conditions: Gastric Cancer, Carcinoma, Non-Small Cell Lung, Gastroesophageal-junction Cancer.

What interventions are being tested in trial NCT04931654?

The interventions under investigation include: AZD7789 (DRUG).

Who is sponsoring clinical trial NCT04931654?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04931654 being conducted?

This trial has 20 study locations across Georgia, Indiana, New York, Tennessee, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.